Efficient access to N-protected derivatives of (R,R,R)- and (S,S,S)-octahydroindole-2-carboxylic acid by HPLC resolution

Tetrahedron Asymmetry

Volumn 18, Issue 19, 2007, Pages 2358-2364

  Sayago, Francisco J ^a   Jiménez, Ana I ^a   Cativiela, Carlos ^a  

^a UNIVERSITY OF ZARAGOZA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; OCTAHYDROINDOLE 2 CARBOXYLIC ACID; PROLINE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CHIRALITY; CHROMATOGRAPHY; DRUG SYNTHESIS; ENANTIOMER; ENANTIOSELECTIVITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; ISOLATION PROCEDURE; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; QUANTUM YIELD;

EID: 35348899589     PISSN: 09574166     EISSN: 1362511X     Source Type: Journal    
DOI: 10.1016/j.tetasy.2007.09.006     Document Type: Article

References (72)

1. In: Kastin A.J. (Ed). Handbook of Biologically Active Peptides (2006), Academic Press, Elsevier, London
2. Cowell S.M., Lee Y.S., Cain J.P., and Hruby V.J. Curr. Med. Chem. 11 (2004) 2785-2798
3. Sagan S., Karoyan P., Lequin O., Chassaing G., and Lavielle S. Curr. Med. Chem. 11 (2004) 2799-2822
4. Gibson S.E., Guillo N., and Tozer M.J. Tetrahedron 55 (1999) 585-615
5. Hruby V.J., Li G., Haskell-Luevano C., and Shenderovich M. Biopolymers (Pept. Sci.) 43 (1997) 219-266
6. Rizo J., and Gierasch L.M. Annu. Rev. Biochem. 61 (1992) 387-418
7. Karoyan P., Sagan S., Lequin O., Quancard J., Lavielle S., and Chassaing G. Substituted Prolines: Syntheses and Applications in Structure-Activity Relationship Studies of Biologically Active Peptides. In: Attanasi O.A., and Spinelli D. (Eds). Targets in Heterocyclic Systems. Chemistry and Properties Vol. 8 (2005), Royal Society of Chemistry, Cambridge 216-273
8. Cativiela C., and Díaz-de-Villegas M.D. Tetrahedron: Asymmetry 11 (2000) 645-732
9. Reiersen H., and Rees A.R. Trends Biochem. Sci. 26 (2001) 679-684
10. Vanhoof G., Goossens F., De Meester I., Hendriks D., and Scharpé S. FASEB J. 9 (1995) 736-744
11. MacArthur M.W., and Thornton J.M. J. Mol. Biol. 218 (1991) 397-412
12. Alfakih K., and Hall A.S. Expert Opin. Pharmacother. 7 (2006) 63-71
13. Menard J., and Patchett A.A. Adv. Protein Chem. 56 (2001) 13-75
14. Hurst M., and Jarvis B. Drugs 61 (2001) 867-896
15. Todd P.A., and Fitton A. Drugs 42 (1991) 90-114
16. Curran M.P., McCormack P.L., and Simpson D. Drugs 66 (2006) 235-255
17. ASCOT Investigators. Lancet 366 (2005) 895-906
18. PROGRESS Collaborative Group. Lancet 358 (2001) 1033-1041
19. Gass J., and Khosla C. Cell. Mol. Life Sci. 64 (2007) 345-355
20. Brandt I., Scharpé S., and Lambeir A.-M. Clin. Chim. Acta. 377 (2007) 50-61
21. García-Horsman J.A., Männistö P.T., and Venäläinen J.I. Neuropeptides 41 (2007) 1-24
22. Rosenblum J.S., and Kozarich J.W. Curr. Opin. Chem. Biol. 7 (2003) 496-504
23. Polgár L. Cell. Mol. Life Sci. 59 (2002) 349-362
24. Bellemère G., Vaudry H., Morain P., and Jégou S. J. Neuroendocrinol. 17 (2005) 306-313
25. Schneider J.S., Giardiniere M., and Morain P. Neuropsychopharmacology 26 (2002) 176-182
26. Morain P., Lestage P., De Nanteuil G., Jochemsen R., Robin J.L., Guez D., and Boyer P.A. CNS Drug Rev. 8 (2002) 31-52
27. Morain P., Robin J.L., De Nanteuil G., Jochemsen R., Heidet V., and Guez D. Br. J. Clin. Pharmacol. 50 (2000) 350-359
28. Barelli H., Petit A., Hirsch E., Wilk S., De Nanteuil G., Morain P., and Checler F. Biochem. Biophys. Res. Commun. 257 (1999) 657-661
29. Portevin B., Benoist A., Rémond G., Hervé Y., Vincent M., Lepagnol J., and De Nanteuil G. J. Med. Chem. 39 (1996) 2379-2391
30. Stewart J.M. Peptides 25 (2004) 527-532
31. Reissmann S., and Imhof D. Curr. Med. Chem. 11 (2004) 2823-2844
32. Regoli D., Allogho S.N., Rizzi A., and Gobeil F.J. Eur. J. Pharmacol. 348 (1998) 1-10
33. Bas M., Bier H., Greve J., Kojda G., and Hoffmann T.K. Allergy 61 (2006) 1490-1492
34. Sorbera L.A., Fernandez-Forner D., and Bayes M. Drug Future 31 (2006) 101-106
35. Abraham W.M., Scuri M., and Farmer S.G. Eur. J. Pharmacol. 533 (2006) 215-221
36. Akbary A.M., Wirth K.J., and Scholkens B.A. Immunopharmacology 33 (1996) 238-242
37. Griesbacher T., and Lembeck F. Br. J. Pharmacol. 107 (1992) 356-360
38. Wirth K., Hock F.J., Albus U., Linz W., Alpermann H.G., Anagnostopoulos H., Henke S., Breipohl G., Konig W., Knolle J., and Scholkens B.A. Br. J. Pharmacol. 102 (1991) 774-777
39. In: Dalko P.I. (Ed). Enantioselective Organocatalysis: Reactions and Experimental Procedures (2007), Wiley-VCH, Weinheim
40. Berkessel A., and Gröger H. Asymmetric Organocatalysis (2005), Wiley-VCH, Weinheim
41. Dalko P.I., and Moisan L. Angew. Chem., Int. Ed. 43 (2004) 5138-5175
42. It should be noted that this nomenclature is ambiguous since all four Oic stereoisomers having an (S) configuration at the α carbon can actually be denoted as l. However, in the text, l-Oic is always used in reference to the (2S,3aS,7aS) compound.
43. Belvisi L., Colombo L., Colombo M., Di Giacomo M., Manzoni L., Vodopivec B., and Scolastico C. Tetrahedron 57 (2001) 6463-6473
44. Pyne S.G., Javidan A., Skelton B.W., and White A.H. Tetrahedron 51 (1995) 5157-5168
45. Vincent M., Marchand B., Remond G., Jaguelin-Guinamant S., Damien G., Portevin B., Banmal J., Volland J., Bouchet J., Lambert P., Serkiz B., Luitjen W., Laubie M., and Schiawi P. Drug Des. Discovery 9 (1992) 11-28
46. Blankley C.J., Kaltenbronn J.S., DeJohn D.E., Werner A., Bennett L.R., Bobowski G., Krolls U., Johnson D.R., Pearlman W.M., Hoefle M.L., Essenburg A.D., Cohen D.M., and Kaplan H.R. J. Med. Chem. 30 (1987) 992-998
47. Vincent M., Remond G., Portevin B., Serkiz B., and Laubie M. Tetrahedron Lett. 23 (1982) 1677-1680
48. Kurokawa M., and Sugai T. Bull. Chem. Soc. Jpn. 77 (2004) 1021-1025
49. Hirata, N. U.S. Patent 0,106,690, 2005.
50. Yamamoto C., and Okamoto Y. Bull. Chem. Soc. Jpn. 77 (2004) 227-257
51. Yashima E. J. Chromatogr., A 906 (2001) 105-125
52. Okamoto Y., and Yashima E. Angew. Chem., Int. Ed. 37 (1998) 1020-1043
53. Zhang T., Nguyen D., Franco P., Murakami T., Ohnishi A., and Kurosawa H. Anal. Chim. Acta 557 (2006) 221-228
54. Zhang T., Kientzy C., Franco P., Ohnishi A., Kagamihara Y., and Kurosawa H. J. Chromatogr., A 1075 (2005) 65-75
55. Ikai T., Yamamoto C., Kamigaito M., and Okamoto Y. Polym. J. 38 (2006) 91-108
56. Ali I., and Aboul-Enein H.Y. J. Sep. Sci. 29 (2006) 762-769
57. Franco P., Senso A., Oliveros L., and Minguillón C. J. Chromatogr., A 906 (2001) 155-170
58. Zhang T., and Franco P. Analytical and Preparative Potential of Immobilized Polysaccharide-Derived Chiral Stationary Phases. In: Subramanian G. (Ed). Chiral Separation Techniques (2007), Wiley-VCH, Weinheim 99-134
59. Royo S., Jiménez A.I., and Cativiela C. Tetrahedron: Asymmetry 17 (2006) 2393-2400
60. Lasa M., López P., and Cativiela C. Tetrahedron: Asymmetry 16 (2005) 4022-4033
61. Jiménez A.I., López P., and Cativiela C. Chirality 17 (2005) 22-29
62. Cativiela C., Lasa M., and López P. Tetrahedron: Asymmetry 16 (2005) 2613-2623
63. Gil A.M., Buñuel E., López P., and Cativiela C. Tetrahedron: Asymmetry 15 (2004) 811-819
64. Cativiela C., López M., and Lasa M. Eur. J. Org. Chem. (2004) 3898-3908
65. Alías M., López P., and Cativiela C. Tetrahedron 60 (2004) 885-891
66. Royo S., López P., Jiménez A.I., Oliveros L., and Cativiela C. Chirality 14 (2002) 39-46
67. Alías M., Cativiela C., Jiménez A.I., López P., Oliveros L., and Marraud M. Chirality 13 (2001) 48-55
68. Jiménez A.I., López P., Oliveros L., and Cativiela C. Tetrahedron 57 (2001) 6019-6026
69. Cativiela C., Díaz-de-Villegas M.D., Jiménez A.I., López P., Marraud M., and Oliveros L. Chirality 11 (1999) 583-590
70. D = -23.0 (c 0.97, MeOH). This sample was purchased from NeoMPS SA (Strasbourg, France).
71. Sheldrick G.M. shelxs-97, Program for the Solution of Crystal Structures (1997), University of Göttingen, Göttingen
72. Sheldrick G.M. shelxl-97. Program for the Refinement of Crystal Structures (1997), University of Göttingen, Göttingen